Cargando…
Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies
The era of gene therapy has begun. In recent years, potentially breakthrough datasets and rapidly expanding company pipelines have begun to overshadow the unfulfilled promise characteristic of the gene therapy sector in decades prior. One barometer for progress in the space can be seen in stock mark...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Mary Ann Liebert, Inc., publishers
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312046/ https://www.ncbi.nlm.nih.gov/pubmed/30547692 http://dx.doi.org/10.1089/humc.2018.29037.gam |